COMPARE · Data as of August 24, 2026
ABBV vs BHC
Verdict: Side-by-side breakdown using the Bull Rankings model. ABBV scored 63.6, BHC scored 71.3 — BHC leads.
Compare another set
ABBV
AbbVie Inc.
63.6
$264.52 · $467.4B
fundamentals as of
Score gap
7.7
BHC leads
BHC
Bausch Health Companies Inc.
71.3
$6.68 · $2.5B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- Fastest growthABBV+10.4%
- Highest qualityABBV71 / 100
- Largest discount to fair valueBHC-86%
Side by side · every name on one set of axes
The model, pillar by pillar (0–100 each)
ABBV
stronger →← stronger
BHC
71
Qualityreturns · margins · balance sheet
63
66
Growthrevenue & earnings expansion
64
55
Valuevaluation vs sector peers
91
ABBV is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
ABBV
BHC
$18.2bA-
FCF
$1.4bC+
+10.4%B
Rev
+10.1%B
74.5xC
P/E
—
0.43A
PEG
0.01A
—
P/S
0.2xA
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
ABBV
BHC
31% above
Price vs fair valuelower is cheaper
86% below
~17%/yr
Growth the price implies10-yr FCF · lower = less priced in
decline
-35%
1-yr DCF upside
+677%
-24%
5-yr DCF upside
+599%
-3%
10-yr DCF upside
+504%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
ABBV
Why this score
- Raising its dividend
BHC
The companies
ABBVAbbVie Inc.
Why now
Drug Manufacturers - General · market cap $467.4b. Trading near 52-week high of $267.47 — momentum setup, limited technical margin of safety. Revenue growing +10%, comfortably above the S&P median. PEG 0.43 — paying under fair value for the growth rate. 29 sell-side analysts rate this a Buy with a mean 1-yr target of $276.59 (implying +5% upside).
Moat
Free cash flow runs well ahead of reported net income — non-cash charges (depreciation, intangible amortization) are holding down GAAP earnings while cash generation stays strong. $467.4b market cap places it among the largest companies in the sector — distribution, R&D, and customer-acquisition costs amortize across a base peers can't replicate. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trailing P/E 74.5x prices in sustained high growth — any quarter that disappoints triggers sharp re-rating. Trading within 1% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. ROE -106% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.
BHCBausch Health Companies Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap $2.5b. 17% off the 52-week high of $8.00. Revenue growing +10%, comfortably above the S&P median. PEG 0.01 — paying under fair value for the growth rate. 5 sell-side analysts publish a mean 1-yr target of $7.50 (implying +12% upside).
Moat
ROE 62% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Currently unprofitable (margin -10.1%) — path to GAAP profitability is the core thesis risk. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where ABBV and BHC diverge
On the headline score the gap is 7.7 points in favor of BHC. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.
- ValueABBV 54.7 · BHC 90.6BHC +35.9
- QualityABBV 71.2 · BHC 62.9ABBV +8.3
- GrowthABBV 65.9 · BHC 63.7level
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.